Update on FDA approval of XIPERE for macular edema associated with uveitis from Bausch + Lomb

Video

Bausch + Lomb's Yolande Barnard shares an update on the FDA approval of XIPERE for the treatment of macular edema associated with uveitis.

Modern Retina™'s David Hutton speaks with Yolande Barnard, vice president and general manager, U.S. Pharmaceuticals, Bausch + Lomb, on the company's latest FDA approval of XIPERE (triamcinolone acetonide injectable suspension) for the treatment of macular edema associated with uveitis.

XIPERE is the first—and currently only— FDA-approved therapy utilizing suprachoridal administration.

The American Academy of Ophthalmology (AAO) annual meeting was held November 12 to 15 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The event included Subspecialty Days and a virtual component for remote participation.

Related Content: Additional AAO Content | Ophthalmology | Conference Coverage

Newsletter

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Recent Videos
Victor Gonzalez, MD, speaks about his Clinical Trials at the Summit presentation, focusing on retinitis pigmentosa therapy MCO-010 (Nanoscope Therapeutics)
Carl Danzig, MD, director of vitreo-retinal services at the Rand Eye Institute in Deerfield Beach, Florida, shared an update on his research in OCS-01 drops for diabetic macular edema during ARVO
© 2025 MJH Life Sciences

All rights reserved.